Pharmaceuticals, Biotechnology and Life Sciences
Schreiner MediPharm has launched a new tamper-evident security concept for luer-lock syringes: Cap-Lock features a combination of a cap adapter and label that firmly seals prefilled syringes and reliably indicates any first opening.
The Janssen has filed for a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking first-in-class approval of guselkumab brand Tremfya, for the treatment of adult patients with active psoriatic arthritis (PsA), and expects to submit a marketing application to the European Medicines Agency seeking approval of TREMFYA as a treatment for PsA before the end of the year.
The addition of daratumumab – or in this particular study – Darzalex to bortezomib, lenalidomide and dexamethasone (VRd) induced higher response rates in newly diagnosed patients with multiple myeloma who were eligible for high-dose therapy and autologous stem cell transplantation (ASCT) compared with VRd alone.
Catalyst Pharmaceuticals, said Friday it will not conclude the offering of shares of its common stock announced on Wednesday, September…
Sygnature Discovery has moved its US office to the heart of the Cambridge–Boston biotech hub, describing it as a small but a significant move, as it will have more than 100 pharma/biotech companies within a mile of the new office, and many more in the wider Boston–Cambridge area.
BioPharma Credit, the specialist life sciences debt investor, is in a senior secured note purchase agreement for the issuance and sale of senior secured notes in an aggregate original principal amount of up to $150 million by OptiNose US, Inc. alongside BioPharma Credit Investments, a private fund also investing in life sciences debt managed by Pharmakon Advisors launched in June 2019.
Strekin AG, a biopharmaceutical company focused on treatments for hearing loss, has successfully completed patient recruitment in its study called Restore.
Roche’s study met a goal, comparing a lung cancer therapy Tecentriq with cisplatin and pemetrexed as the initial monotherapy compared in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (Wild-Type or WT).
Merck has ensured Breakthrough Therapy Designation for the investigational targeted therapy tepotinib in USA, for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations who progressed following platinum-based cancer therapy.
Glenmark Pharmaceuticals said Tuesday it has bagged the final USFDA’s approval for its generic version of Mylan’s Olux-E Foam, Clobetasol Propionate Foam.